Latest Ratios: P/E Ratio 0.2x · EV/EBITDA N/A · ROE 4099.5%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $8M | $35M | $53M | $86M | $1.5B | $1.3B | $3.3B | $3.7B | $3.9B | $3.5B | $1.3B |
| Enterprise Value | $-39611795 | $-12374460 | $76M | $143M | $1.4B | $1.2B | $2.7B | $3.6B | $3.9B | $2.9B | $1.3B |
| P/E Ratio → | 0.24 | 0.19 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.56 | 5.51 | 1.79 | 1.84 | 10.65 | 5.53 | 18.90 | 14.48 | 18.27 | 27.53 | 7.48 |
| P/B Ratio | 1.84 | 7.93 | — | — | — | 5.68 | 7.55 | 6.94 | 7.36 | 5.94 | 7.67 |
| P/FCF | — | — | — | — | — | — | 42.94 | — | — | — | 229.29 |
| P/OCF | — | — | — | — | — | — | 40.84 | — | — | — | 188.90 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -1.92 | 2.55 | 3.06 | 10.18 | 5.23 | 15.28 | 14.19 | 18.31 | 22.95 | 7.05 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 34.71 | — | — | — | 216.24 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.4% | 91.4% | 47.5% | 91.5% | 85.6% | -90.9% | 95.0% | 99.6% | -10.7% | -56.4% | -4.2% |
| Operating Margin | -712.7% | -712.7% | -507.8% | -689.5% | -213.9% | -122.6% | -108.8% | -34.8% | -40.7% | -97.6% | -29.9% |
| Net Profit Margin | 2848.6% | 2848.6% | -160.6% | -607.3% | -208.7% | -123.3% | -107.4% | -30.0% | -40.6% | -100.4% | -34.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4099.5% | 4099.5% | — | — | -258.0% | -86.5% | -38.8% | -14.5% | -15.6% | -33.3% | -35.2% |
| ROA | 109.8% | 109.8% | -14.9% | -55.0% | -42.4% | -36.2% | -22.5% | -8.9% | -9.7% | -18.4% | -13.1% |
| ROIC | — | — | — | — | -500.0% | -137.3% | -109.1% | -13.4% | -24.0% | -174.8% | -40.8% |
| ROCE | -53.5% | -53.5% | -104.8% | -119.0% | -68.0% | -47.6% | -27.1% | -11.6% | -10.7% | -20.0% | -13.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.44 | 0.09 | 0.10 | 0.18 | 0.17 | 0.56 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -10.70 | — | — | — | -0.31 | -1.45 | -0.14 | 0.01 | -0.99 | -0.44 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -8.23 | — | — | — | -13.05 |
| Interest Coverage | -6.66 | -6.66 | -17.60 | -38.93 | -203.77 | -324.21 | -77.57 | -25.65 | -6.84 | -11.42 | -4.76 |
Net cash position: cash ($48M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.39 | 3.39 | 1.47 | 1.52 | 1.80 | 2.10 | 4.63 | 6.84 | 7.75 | 9.69 | 4.09 |
| Quick Ratio | 3.26 | 3.26 | 1.45 | 1.33 | 1.65 | 1.96 | 4.53 | 6.77 | 7.75 | 9.69 | 4.09 |
| Cash Ratio | 3.04 | 3.04 | 0.38 | 1.08 | 1.54 | 1.80 | 4.21 | 5.19 | 6.98 | 9.52 | 3.89 |
| Asset Turnover | — | 0.05 | 0.14 | 0.11 | 0.23 | 0.30 | 0.21 | 0.30 | 0.24 | 0.14 | 0.38 |
| Inventory Turnover | 0.15 | 0.15 | 4.93 | 0.10 | 0.50 | 14.48 | 0.54 | 0.17 | — | — | — |
| Days Sales Outstanding | — | 238.95 | 357.11 | 320.16 | 42.27 | 39.40 | 86.70 | 218.60 | 109.15 | 24.55 | 21.24 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 4.2% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 516.7% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 2.3% | — | — | — | 0.4% |
| Buyback Yield | 0.8% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.8% | 0.2% | 4.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $4M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $3M |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KYNB stock.
Kyntra Bio, Inc.'s current P/E ratio is 0.2x. The historical average is 0.2x. This places it at the 100th percentile of its historical range.
Kyntra Bio, Inc.'s return on equity (ROE) is 4099.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -54.1%.
Based on historical data, Kyntra Bio, Inc. is trading at a P/E of 0.2x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Kyntra Bio, Inc. has 91.4% gross margin and -712.7% operating margin.
Key Metrics
Top Statement Risk
Liquidity erosion amid losses
Metrics are mathematically derived from official filings.
Sub-Book Multiple Masks Operating Losses
According to reported ratio data, KYNB trades at a P/B of 1.84 and P/S of 1.56 while its trailing P/E of 0.24 rests on a one-off net profit rather than recurring earnings power, so the headline multiples are unreliable.
The trailing P/E of 0.24 is an artifact of a $148.5M net income quarter that operating results do not support, since operating margins were negative in most periods. Against peers such as PTCT at 33.75 EV/EBITDA, where earnings are positive, KYNB's multiples lack a comparable earnings anchor, which suggests investors should weight the P/S and P/B more heavily while recognizing that a stockholders' deficit makes book value an unreliable reference point.
Margins Swing on Unstable Revenue Base
Based on reported quarterly figures, KYNB's operating margin ranged from negative 46.5% to positive 74.4%, and net margin swung between negative 36.9% and positive 169.4%, indicating earnings are driven by timing rather than durable operations.
The extreme swings in gross and operating margins point to a revenue base too erratic to anchor a profitability trend, with gross margin moving from negative 31.6% to 136.3%. Compared with peers' net margins such as PTCT at 39.4% and ARWR at negative 160.6%, KYNB's figures appear largely non-representative, and investors should treat operating margin as the more informative measure of earning power while noting that non-operating items appear to dominate reported net income.
Negative Returns Erode Capital Base
As reported in the ratio table, KYNB's ROA moved from negative 13.3% to 94.2% across the period, while ROE turned positive only at 8.5% and 5.1% in recent quarters against a stockholders' deficit, leaving return metrics distorted.
A stockholders' deficit inflates or flips ROE, so the recent positive ROE figures may reflect a shrinking equity base rather than improved profitability. ROIC is largely unavailable, so the compounding question cannot be answered from this data, and the absence of consistent positive returns relative to peers such as PTCT at 60.9% ROIC suggests the capital base has not generated sustained value.
Working Capital Cycle Highly Volatile
Based on reported figures, KYNB's cash conversion cycle swung from 4,636 days to negative 133,059 days, with DSO and DPO moving erratically, indicating working capital timing dominates reported efficiency metrics.
Extreme swings in DIO and DPO, including DPO reaching 286,741 days in one period, suggest the cycle figures reflect accounting timing or balance sheet settlement rather than operational efficiency. Compared with peers, the cycle is not meaningfully comparable, and investors should treat the efficiency signal as unreliable until a stable revenue base emerges.
Current Ratio Compression Signals Pressure
As reported in the balance sheet, KYNB's current ratio compressed from 3.71 in 2025Q3 to 1.16 in 2026Q3 while cash fell to $9.9M against total liabilities of $56.0M, a position that appears thin under stress.
The quick ratio tracking the current ratio closely indicates limited reliance on inventory, but the cash buffer of $9.9M against $56.0M of liabilities leaves little room for absorbing further operating burn. The reported cash flow pattern suggests investors should monitor whether the company can sustain obligations without additional capital, though the data alone does not establish financing access.
Misapplied P/E Obscures True Risk
The most commonly misapplied metric here is trailing P/E, which at 0.24 for KYNB appears attractive but reflects a single non-recurring net income quarter rather than the negative operating earnings shown across most reported periods.
Trailing P/E is misleading because the $148.5M profit is driven by non-operating swings and working capital timing rather than core operations, so the multiple implies cheapness that operating results do not support. A more appropriate lens is EV-to-sales or cumulative operating cash flow over multiple periods, which better reflects the sustained cash burn and accumulated deficit that the headline multiple obscures.